Anixa Biosciences Reports Encouraging Patient Survival Observations in Ovarian Cancer CAR-T Trial; Achieves Regulatory Approval Enabling Major Dose Escalation
Rhea-AI Summary
Anixa Biosciences (NASDAQ: ANIX) reported encouraging survival observations from its Phase 1 ovarian cancer intra-peritoneal CAR-T trial and obtained regulatory approval to escalate doses substantially.
Twelve patients treated; seven have exceeded expected median survival (~3–4 months), including one at 28 months and three >12 months. No dose-limiting toxicities observed; amended protocol allows dosing up to 1×10⁹ cells/kg and adds lymphodepletion prior to higher-dose cohorts.
AI-generated analysis. Not financial advice.
Positive
- Seven of 12 patients exceeded expected median survival (~3–4 months)
- One patient survived 28 months after treatment
- Protocol amendment permits dosing up to 1×10⁹ cells/kg (100× increase)
- No dose-limiting toxicities observed to date
- Amended design adds lymphodepletion to potentially enhance CAR-T activity
Negative
- Small sample size: only 12 patients treated so far
- Survival observations described as anecdotal and not conclusive efficacy proof
- Current positive outcomes occurred at doses described as below optimal therapeutic range
News Market Reaction – ANIX
On the day this news was published, ANIX gained 0.68%, reflecting a mild positive market reaction. Argus tracked a trough of -15.1% from its starting point during tracking. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $667K to the company's valuation, bringing the market cap to $98.80M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
ANIX rose 7.64% while several biotech peers like SRZN (+6.94%), STTK (+6.5%) and TCRX (+9.78%) also gained, but scanner data shows no coordinated sector momentum and PYXS declined 2.58%, pointing to stock-specific drivers.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 02 | Naming / branding | Positive | -3.3% | USAN Council approval of non-proprietary name for ovarian cancer CAR-T. |
| Jan 27 | IP / patent news | Positive | -0.3% | Notice of Allowance for Mexican patent on breast cancer vaccine technology. |
| Dec 15 | Trial ownership shift | Positive | -8.9% | Transfer of breast cancer vaccine IND to Anixa and plan for Phase 2. |
| Dec 11 | Clinical data update | Positive | -6.4% | Positive Phase 1 breast cancer vaccine data with primary endpoints met. |
| Dec 10 | Investor event | Positive | +1.4% | Announcement of Water Tower Research fireside chat discussing Phase 1 data. |
Recent fundamentally positive updates have often seen negative next-day price reactions, indicating a tendency for good news to be sold into.
Over the past few months, Anixa has reported several positive oncology milestones. These include Phase 1 breast cancer vaccine data meeting primary endpoints with immune responses in 74% of participants, completion of the IND transfer and plans for Phase 2, and international patent expansion in Mexico. The company also secured a USAN non-proprietary name for its ovarian cancer CAR-T therapy. Despite these constructive developments, prior announcements on Dec 10–15, 2025 and Jan 27–Feb 2, 2026 often saw short-term share price declines, contrasting with today’s more favorable reaction to encouraging CAR-T survival and dose-escalation news.
Regulatory & Risk Context
Anixa has an active Form S-3 shelf filed on 2025-09-10, allowing issuance of various securities such as common stock, preferred stock, warrants and units. The filing is currently noted as not effective and shows no recorded usage in recent 424B supplements, indicating capacity remains unused in the provided data.
Market Pulse Summary
This announcement highlights encouraging early survival outcomes in a 12‑patient Phase 1 ovarian cancer CAR-T trial and regulatory approval to escalate doses up to 1×10⁹ cells/kg. The absence of dose-limiting toxicities and the introduction of lymphodepletion support a more expansive exploration of efficacy in a heavily pretreated population. In context of prior positive vaccine data and recent insider buying, key items to watch include safety at higher doses, durability of responses, and future financing steps under the existing shelf registration.
Key Terms
car-t medical
dose-limiting toxicities medical
intra-peritoneal medical
institutional review board (irb) regulatory
cells/kg medical
lymphodepletion medical
hematologic cancers medical
u.s. food and drug administration regulatory
AI-generated analysis. Not financial advice.
Multiple patients substantially exceed expected survival at low dose levels; absence of dose-
limiting toxicities supports escalation to doses up to 100x higher
Trial expansion reflects growing confidence in intra-peritoneal CAR-T delivery and introduces
lymphodepletion to potentially enhance efficacy
Anixa to participate in Water Tower Research fireside chat at 11:00am ET on February 10, 2026
to discuss trial observations
The ongoing Phase 1 trial is enrolling adult women with recurrent ovarian cancer, who have failed standard of care chemotherapy, and progressed after two or more prior therapies. To date, twelve patients have been treated in the trial at four dosage levels. Of these patients, seven have lived beyond their expected median survival of approximately three to four months, based on disease stage and prior therapy history. One patient survived 28 months following treatment, three patients have survived greater than one year following treatment (17, 15 and 14 months, respectively) and three patients have survived 11, 8 and 8 months, respectively. Three patients that have reached 15, 14 and 8 months remain alive, and one additional patient who was treated more recently, is also currently alive.
While the study is designed to primarily demonstrate safety, Anixa believes this pattern of extended survival represents encouraging, albeit anecdotal, evidence of clinical activity in a patient population with limited therapeutic options. These survival observations have been accompanied by a clean safety profile. Importantly, no dose-limiting toxicities (DLTs) have been observed to date, prompting Anixa's partner, Moffitt Cancer Center ("Moffitt"), to obtain Institutional Review Board (IRB) approval for a protocol amendment that permits significant dose escalation.
Under the amended protocol, dosing may increase from the original range of 1×10⁵ to 1×10⁷ CAR-positive cells per kilogram of body weight ("cells/kg") to as high as 1×10⁹ cells/kg, representing a two-order-of-magnitude increase. If no DLTs are observed at this level, additional escalation may be pursued at the discretion of the principal investigator.
Anixa and Moffitt believe the favorable safety profile observed to date is partially attributable to the direct intra-peritoneal delivery of CAR-T cells, which differs from conventional intravenous administration and may reduce systemic toxicity while enhancing localized tumor targeting.
Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences, stated, "Although these patients were treated at doses we believe are below the optimal therapeutic range, we are encouraged by the number of individuals who have lived far longer than expected."
As part of the amended study design, the next patient cohort will receive 1×10⁷ cells/kg following treatment with cyclophosphamide and fludarabine, a preparatory regimen known as lymphodepletion. Lymphodepletion reduces competing immune cells, creating a more favorable environment for CAR-T expansion, persistence, and activity. While lymphodepletion is routinely used in CAR-T therapies for hematologic cancers, its role in solid tumors remains investigational. Anixa, Moffitt, and the
Dr. Robert Wenham, Chair of the Gynecologic Oncology Program at Moffitt and principal investigator of the trial, added, "The absence of dose-limiting toxicities observed thus far has given us the flexibility to safely explore higher dose levels than originally planned. With regulatory approval now in place, the program is positioned to advance into higher-dose evaluation under the amended protocol. This amendment allows us to further evaluate both safety and potential therapeutic benefit as the study advances."
Dr. Kumar will further discuss the observations in the clinical trial, as well as provide updates on Anixa's plans for 2026, in the upcoming Water Tower Research Fireside Chat Series taking place on Tuesday, February 10, 2026, at 11:00am ET. Interested parties can register for the event at: Fireside Chat Registration.
About Lira-cel, Anixa's CAR-T Therapy for Recurrent Ovarian Cancer
Liraltagene autoleucel, or lira-cel, uniquely targets the follicle-stimulating hormone receptor (FSHR), which is selectively expressed on ovarian cells, tumor vasculature, and certain cancer cells, but not in healthy tissue. The ongoing Phase 1 trial (ClinicalTrials.gov NCT05316129) is enrolling adult women with recurrent ovarian cancer who have progressed after at least two prior therapies.
About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of liraltagene autoleucel, or lira-cel, an ovarian cancer immunotherapy being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. This technology is differentiated from other cell therapies as the natural ligand of the FSHR receptor, FSH, binds to the FSHR receptor on the tumor cell instead of an antibody fragment. Moffitt is a world leader in cancer immunotherapy treatments, pioneering next-generation cell therapies such as CAR-T, and tumor infiltrating lymphocytes (TILs) to harness the power of the immune system. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. The breast and ovarian cancer vaccines were developed at Cleveland Clinic and exclusively licensed to Anixa. Cleveland Clinic is entitled to royalties and other commercialization revenues from the Company related to these vaccine technologies. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on LinkedIn, X, Facebook and YouTube.
Forward-Looking Statements
Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.
Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808
View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-reports-encouraging-patient-survival-observations-in-ovarian-cancer-car-t-trial-achieves-regulatory-approval-enabling-major-dose-escalation-302681799.html
SOURCE Anixa Biosciences, Inc.